Although prostate-specific antigen (PSA) has been shown to be an auxiliary instrument in the management of prostate cancer, there is still an urgent need for better biomarkers. More sensitive and specific biomarkers are needed for a more precise and accurate diagnosis in the early stages of the disease. Furthermore, biomarkers are required for prognostic and predictive purposes. Recent advances in the field of genomics and proteomics have resulted in the identification of promising biomarkers for prostate cancer. This article reviews and discusses several of the most promising candidate biomarkers for prostate cancer.
|Translated title of the contribution||Biomarkers for prostate cancer. Molecular approaches to assess prognosis|
|Number of pages||8|
|Publication status||Published - 08.2007|